Press Room

News / May 06, 2021

Science Turnaround - Case Studies

Case Studies presented by our scientists: how alternative scenarios accelerated progress and improved results allowing our clients’ products to perform better.

Science Turnaround - Case Studies | Hovione

Welcome to the new “Science Turnaround” Series

Our multinational team partners with global customers to help deliver lifesaving and life changing medicines for patients all over the world. Most of the projects we are involved in are complex and challenge us to innovate in order to allow our clients’ products to perform better. 

In this new compilation of Case Studies presented by our scientists, we share how Hovione’s multi-disciplinary teams’ expertise, scientific rigor and out-of-the-box thinking allowed us to see alternative scenarios, accelerating progress and improving results.

 

Click on the image to play the video
Case Study - Enabling lean manufacturing with Process Analytical Technologies (PAT) | Hovione
https://go.hovione.com/case-study-enabling-lean-manufacturing-PAT

 

Case Study #6 - “Enabling lean manufacturing with Process Analytical Technologies (PAT)"

In this case study, Ricardo Sousa explains how a 20h bottleneck was eliminated by replacing a loss on drying method with NIR, decreasing the stocking time to 5 hours.
Case Study - De-risking scale-up of DPI formulations | Hovione
https://go.hovione.com/case-study-de-risking-scale-up-DPI-formulations

 

Case Study #5 - “De-risking scale-up of DPI formulations”

In this case study, João Pereira and Beatriz Fernandes explain how to approach the scale-up of DPI formulations from lab to commercial scale by maintaining scale-independent blending parameters and the capsule filling mechanism, avoiding impact on processability and final product performance. 
Case Study - Hazardous Chemistry at High Temperature | Hovione
https://go.hovione.com/case-study-hazardous-chemistry-high-temperature

 

Case Study #4 - “Hazardous Chemistry at High Temperature”

In this case study, Rudi Oliveira explains how a hazardous chemical process was approached and how continuous flow was applied to achieve a safer and more efficient process at scale.
Case Study - Understanding crystallization | Hovione
https://go.hovione.com/case-study-understanding-crystallization-0

 

Case Study #3 - "Understanding crystallization"

In this case study, Filipe Vultos and Liliana Silva explain the approach taken to study the physical stability of a multicomponent amorphous solid dispersion formulation with the aim of achieving a better understanding of the crystallization events occurring during stability studies.
Case Study - Reduction of QC burden | Hovione
https://go.hovione.com/case-study-pat-impact-on-reduction-qc-burden

 

Case Study #2 - "Reduction of QC burden"

In this case study, André Cruz explains how an analytical bottleneck, that resulted from a combination of a time-consuming analytical technique with a process that involved high throughput of samples, was approached and how Chemometrics allied with Near infrared (NIR) spectroscopy were applied to achieve a faster analytical response that potentiate the increase of productivity for both QC and Production areas.
Case Study - In water we go | Hovione
https://go.hovione.com/case-study-in-water-we-go-process-development

 

Case Study #1 - “In water we go”

In the first case study, Susana Lucas explains how a multistep chemical process was approached toward a new synthetic route to achieve an efficient and highly sustainable one-pot scalable process.



 



 



 

Wondering if your projects can achieve better results this year?

 

Contact our experts today



 



 



 



 



 

Also in the Press Room

See All

With key expansions coming to fruition on either side of the pond, specialist CDMO Hovione is making sure that drugmakers can access its particle engineering expertise across multiple geographies.  That flexibility will be key for the Portugal-based company in the coming years as the pharmaceutical industry continues to embrace more regional supply chains. In a recent interview, Hovione's David Basile, VP of technical operations for the Americas, discussed this trend and the manufacturer's expansion project, which is set to come online in New Jersey next month.  In the coming weeks, Hovione plans to debut a new spray drying expansion at its campus in East Windsor, New Jersey. The company has invested $100 million to expand its campus, including new construction and the acquisition of an additional facility and greenfield land.  Specifically, one of two pharmaceutical spray drying-3 units, or PSD-3 units, will come online in the coming weeks to tackle amorphous active pharmaceutical ingredients (APIs) and amorphous solid dispersions, according to the company. With some 80% of new small molecules in development insoluble in water, Hovione’s particle engineering and amorphous solid dispersion platform helps medicine developers improve the solubility, bioavailability, and, in some cases, the stability of their drug candidates, Basile said.  The company boasts spray dryers from the lab scale to PSD3 at its original facility in East Windsor, in addition to the pair of large-scale machines about to be activated at the campus' new facility.  “We’re going for a single, unified site with capabilities across the campus to do drug substance through finished drug product under one governance and quality system,” - Basile told Fierce.   Read the full article at FiercePharma.com

Article
Fierce Pharma, 26 March 2026

As expansions come online, CDMO Hovione aims to meet industry's 'dual supply and sourcing' zeal: exec

Mar 26, 2026

Twenty companies presented at the annual kickoff to DCAT Week. The Drug, Chemical & Associated Technologies Association (DCAT) opened DCAT Week 2026 with its Member Company Announcement Forum. The kickoff to the annual event in New York City, underway from March 23–26, 2026, showcased 20 companies. These were selected based on their announcements’ “news priority, criticality, and interest” to DCAT member companies. The following is a summary of highlights from the presentations, supplemented by additional information provided by some of the companies. (...) Hovione Hovione’s Vice President of Technical Operations for the Americas, David Basile, delivered the company’s Member Company Announcement Forum presentation. Basile will be speaking exclusively with Contract Pharma during DCAT Week, so check back for more on Hovione’s latest.   Read the full article at ContractPharma.com    

Press Clipping
Contract Pharma, 23 March 2026

DCAT Member Company Announcement Forum 2026: An Inside Look

Mar 23, 2026

With more than six decades of experience in pharmaceutical development and manufacturing, Hovione is an international CDMO offering a comprehensive range of services for New Molecular Entities (NMEs), including drug substances, intermediates, and drug products. The company also supplies niche generic APIs and delivers advanced technologies supporting multiple drug delivery platforms, including oral, injectable, inhalation, and topical formulations.  Today, Hovione employs 2,500 people worldwide and operates 900 m3 of manufacturing capacity across four sites in Europe, the U.S. and Asia. Japan has played an important role in the company’s global strategy since its early years. Initial export activities were followed in 2017 by the establishment of a Japanese subsidiary in Osaka.   Read the full article in Japanese at Yakuji.co.jp Read the article translated in English  

Press Clipping
Yakuji Nippo Magazine, 13 March 2026

International CDMO strengthens its presence in Japan: from active pharmaceutical ingredients to formulations, all at the same location

Mar 13, 2026

Also in Events

See All